Redesigning the ₹499 Regulatory Readiness Report (Tier 1)
The source draft pack is on my desktop: ClearPath draft-submission-pack-user. Read it for case facts only — do not mirror its structure. It's a 19-page Tier 2/3 consultant dossier (Intended Use Statement, Device Description, Essential Principles checklist, Algorithm Change Protocol, appended blank CDSCO forms). That is exactly what the ₹499 report must not be. Treat it as raw input, not a template.
If the file path doesn't resolve, regenerate from these facts instead:

Product: AI/ML SaMD that flags suspected early-stage Alzheimer's from brain MRI scans; advisory output reviewed by radiologists
Applicant: Raunaq Pradhan · Assessment ID a4bd6e06-6650-4c8d-91a5-9d47c977eef4 · Generated 25 Apr 2026
Likely classification: Class B/C SaMD (leaning C), AI-CDS / diagnostic-support
Triggers: AI-assisted diagnosis · critical disease indication · informs clinical management · novel (no Indian predicate) · sensitive MRI data · adaptive AI model
Likely pathway: domestic manufacture → central CDSCO route, Form MD-7; Form MD-12 test licence for the clinical investigation; ACP/PCCP expected per Oct 2025 SaMD draft
Readiness: 0/10 — no ISO 13485 QMS, no IEC 62304 lifecycle, no EC-approved clinical validation
Parallel obligations: DPDP (MRI = sensitive personal data), ICMR 2023 AI ethics, ABDM/NABH conditional
Timeline: ~14–22 months to submission-ready, driven by clinical validation
Clinical investigation: likely required (novel indication)

Build the report to the Tier 1 spec — 4–6 pages, six sections only:

Regulatory Scorecard (hero, ~1 page) — likely classification, confidence score, complexity, pathway, clinical-investigation flag, timeline, cost range, readiness score, top gaps, risk level, recommended next action, and a "what triggered this classification" block. Visual: status indicators, confidence bars, scorecard layout.
Your Likely Regulatory Pathway — why this class applies to this product, which authority, which forms, the step sequence, test licence / ACP relevance. Plain English, "what this means for you" framing.
Readiness Gap Analysis (most important) — prioritized table: Priority | Gap | Why it matters | Suggested next step | Estimated effort. Founder-friendly language ("reviewers will likely expect…"), not "nonconformity."
Timeline + Cost Estimator — phased roadmap (Phase → Duration → What happens), bottlenecks, realistic Indian-context cost ranges.
Reviewer Insights — what CDSCO reviewers will likely look for (intended-use consistency, clinical validation, AI update controls, cybersecurity, Indian population relevance, explainability).
Smart Examples — annotated good-vs-bad snippets (intended-use wording, claim wording, risk justification). Snippets only, never full forms.

Delete entirely (these belong to Tier 2 Submission Workspace and collapse the upgrade funnel): the appended blank forms, the full Essential Principles checklist, the glossary, the standalone Device Description, and the full Algorithm Change Protocol write-up.
Fix the certainty inconsistency: the draft pack contradicts itself — Executive Summary says a hard "Class C," but the Snapshot and Section 09 hedge to "Likely Class B/C" / "forms TBD." Per the ClearPath SKILL.md certainty rules, the whole report uses the softened form. Run softenCertainty() as the final pass; never let a hard "Class C," "must," or "is required" through.
Tone and format: premium SaaS-onboarding feel (Stripe Atlas / ClearTax / Mercury), card/table/checklist-driven, skimmable, low jargon. Every section answers "why does this matter to me?" Brand system from the SKILL.md — Teal Trust palette, Georgia serif + Inter sans, colors from the Tailwind config not inline.
Boundary: the report explains what's required, why it matters, likely gaps, effort, and reviewer expectations — it does not generate MD-7 drafts, DMFs, QMS docs, or submission-ready artifacts. It should leave the founder thinking "I understand my situation and what to do next — and I probably need the Workspace to execute it."